- Tumors1000+
- Cancer683
- Pathologic Processes655
- Pathology651
- Nervous System Diseases517
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer683
- Pathologic Processes655
- Pathology651
- Nervous System Diseases517
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- PD-L1 negative
- EGFR negative
- ALK negative
- EGFR positive
- ER negative
- PR negative
- KRAS positive
- BRAF positive
- CD20 positive
- ALK positive
- BRAF negative
- BRCA1 positive
- ROS1 negative
- BRCA2 positive
- HLA-A positive
- p16 positive
- HLA positive
- PIK3CA positive
- HR positive
- MET positive
- MYC positive
- ROS1 positive
- TP53 positive
- HLA-A negative
- RET positive
- BCR-ABL1 positive
- HLA negative
- IDH positive
- RB1 negative
- RB1 positive
- p16 negative
- BCL2 positive
- HBsAg positive
- L858R positive
- MET negative
- anti-dsDNA positive
- ctDNA positive
- ANA positive
- Bcl6 positive
- CD19 positive
- Ex19del positive
- IDH negative
- Philadelphia chromosome positive
- RET negative
- TP53 negative
- dMMR positive
- p53 positive
- BRCA positive
- BRCA1 negative
- BRCA2 negative
- CCND1 positive
- FMR1 positive
- HPV negative
- MDM2 positive
- MSI-H positive
- MSS positive
- NRAS positive
- NTRK negative
- PALB2 positive
- PTEN positive
- T790M positive
- TROP2 negative
- TROP2 positive
- TTR positive
- APP positive
- C5 positive
- CFTR positive
- COL7A1 positive
- EBV positive
- FGFR2 positive
- FGFR3 positive
- HPV positive
- HRAS positive
- HbSS positive
- IGHV negative
- IGHV positive
- KRAS negative
- MGMT negative
- MMR positive
- MSI-H negative
- NF1 positive
- NRAS negative
- NTRK positive
- PSEN1 positive
- PSEN2 positive
- PTEN negative
- Philadelphia chromosome negative
- RAS negative
- RF positive
- SPINK5 positive
- anti-Sm positive
- dMMR negative
- 11q negative
- 11q positive
- ABCA4 positive
- AFP positive
- ALPL positive
- ATM positive
- Anti-Smith positive
- Aβ1-42 positive
- CD30 positive
- CD5 positive
- COL1A1 positive
- COL1A2 positive
- DMD positive
- Del(17p) negative
- ER/PR positive
- FGFR positive
- FLT3 negative
- FLT3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GLA positive
- HBB positive
- HBV DNA positive
- JAK2 positive
- KIT positive
- Ki-67 positive
- L861Q positive
- MGMT positive
- MSI negative
- MYC negative
- PD-1 negative
- PD-1 positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PiZZ positive
- RAS positive
- S768I positive
- SMN1 positive
- STK11 positive
- TTR negative
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- del(17p) positive
- mesothelin positive
- other sickle cell syndrome variants positive
- t(11;14) negative
- t(11;14) positive
- β-thalassemia positive
- 11q del negative
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p deletion positive
- 17p negative
- 17p positive
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q codeletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- AAV9 antibody titers negative
- AAV9 antibody titers positive
- AAVrh74 antibody titers negative
- ABL-class fusion positive
- ABL-class fusions positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- AGXT positive
- AKT negative
- AKT positive
- ALAS2 positive
- APOL1 positive
- AQP4 positive
- AR positive
- ARID1A positive
- Acetylcholine receptor antibody positive
- Anti-CCP-2 positive
- Anti-HBc IgM negative
- Anti-Ro/SS-A positive
- Anti-SSA (Ro) positive
- Anti-SSB (La) positive
- Anti-Smith antibodies positive
- Antinuclear antibody positive
- Aβ1-40 positive
- Aβ1-42/Aβ1-40 ratio positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Anti-CTLA4 Therapy
- Anti-PD-1/PD-L1 Immunotherapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Avoidance of Activities That Cause Joint Pain
- Biologic Anti-Neoplastic Agent
- Bisphosphonates
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3576 trials
Trials Without a Placebo
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if bitopertin is effective and safe in treating EPP or XLP in participants aged 12 and above. It will investigate whether bitopertin can increase pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the effects of different types of fluids given during surgery on acid-base balance and electrolytes in young patients. Patients will be randomly assigned to receive either normal saline or hypertonic saline
Efficacy & Safety Awards
No Placebo-Only Group
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to test a combination of interventions, including improving sleep, cognitive exercises, and extended pain relief after heart surgery to reduce confusion, agitation, and decline in cognitive function. These interventions are based
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new long-acting HIV treatment for people who still have detectable virus levels despite taking oral medication. The study will look at how well the treatment works, how safe it is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether giving azithromycin along with standard antibiotics to 8,000 women having a cesarean delivery can help reduce infections after childbirth. The study will compare the rates of
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will randomly assign participants to receive either Luminopia dichoptic treatment, Vivid Vision dichoptic treatment, or continued optical correction alone. Participants will be assessed at 9 and 18 weeks
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to see if barzolvolimab is effective, safe, and well-tolerated in adults with Chronic Spontaneous Urticaria who have not responded well to common
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Lazy Eye trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare two treatments for children aged 4 to 7 with lazy eye. One treatment involves watching special movies with a headset for 1 hour per day, 6 days a week
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if plozasiran injection is safe and effective in adults with high triglyceride levels. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new injection called plozasiran in adults with very high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the safety and effectiveness of plozasiran injection in adults with severe high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial compares two drugs, rituximab and mosunetuzumab, in treating patients with low tumor burden follicular lymphoma. Rituximab targets a protein found on B
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the effectiveness of ZILRETTA in reducing pain in people with glenohumeral osteoarthritis when compared to a placebo. The secondary objectives include comparing the pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called pelacarsen to see if it is effective and safe for Black/African American and Hispanic individuals with heart disease and high levels of Lp(a). Participants
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the overall survival of patients with certain types of advanced soft tissue sarcomas who have already tried 2 standard treatments, including one with anthracycline, with a new
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will investigate the impact of a single dose of SRP-9003 on beta-sarcoglycan gene expression in individuals with limb-girdle muscular dystrophy type 2E/R
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Idiopathic Pulmonary Fibrosis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is for people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who have completed treatment with a medicine called BI 1015550 in a previous study. The goal is to see how
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding a monoclonal antibody called dinutuximab to standard treatments like chemotherapy and stem cell transplantation can help treat children with a type of cancer called high risk neuroblast
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50